Litcius/Paper detail

The glycolytic metabolite methylglyoxal covalently inactivates the NLRP3 inflammasome

Caroline Stanton, Chavin Buasakdi, Jie Sun, Ian M. Levitan, Prerona Bora, Sergei Kutseikin, R. Luke Wiseman, Michael J. Bollong

2024Cell Reports12 citationsDOIOpen Access PDF

Abstract

The NLRP3 inflammasome promotes inflammation in disease, yet the full repertoire of mechanisms regulating its activity is not well delineated. Among established regulatory mechanisms, covalent modification of NLRP3 has emerged as a common route for the pharmacological inactivation of this protein. Here, we show that inhibition of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) results in the accumulation of methylglyoxal, a reactive metabolite whose increased levels decrease NLRP3 assembly and inflammatory signaling in cells. We find that methylglyoxal inactivates NLRP3 via a non-enzymatic, covalent-crosslinking-based mechanism, promoting inter- and intraprotein MICA (methyl imidazole crosslink between cysteine and arginine) posttranslational linkages within NLRP3. This work establishes NLRP3 as capable of sensing a host of electrophilic chemicals, both exogenous small molecules and endogenous reactive metabolites, and suggests a mechanism by which glycolytic flux can moderate the activation status of a central inflammatory signaling pathway.

Topics & Concepts

MethylglyoxalBiochemistryInflammasomeGlycolysisMetaboliteChemistryCysteine metabolismCysteineCell biologyEnzymeCovalent bondSignal transductionBiologyReceptorOrganic chemistryInflammasome and immune disordersHeme Oxygenase-1 and Carbon MonoxideAdvanced Glycation End Products research
The glycolytic metabolite methylglyoxal covalently inactivates the NLRP3 inflammasome | Litcius